Saturday February 24th 2018

Teva’s MS drug Copaxone has strong second-quarter sales

JERUSALEM (Reuters) – Teva Pharmaceutical Industries , which this week revealed plans to buy Allergan’s generics drugs business in a $40.5 billion deal, said on Thursday sales of its branded multiple sclerosis drug Copaxone rose 12 percent in the second quarter even though it faces new competition. (Source: Reuters: Health)

Originally posted here: 

Teva’s MS drug Copaxone has strong second-quarter sales

Leave a Comment

More from category

Multiple sclerosis: Skin cells may help to repair nerve damage
Multiple sclerosis: Skin cells may help to repair nerve damage

Researchers could be on the verge of a new treatment for multiple sclerosis; they reveal how transplanting neural stem [Read More]

Medical News Today: Multiple sclerosis: Skin cells may help to repair nerve damage
Medical News Today: Multiple sclerosis: Skin cells may help to repair nerve damage

Researchers could be on the verge of a new treatment for multiple sclerosis; they reveal how transplanting neural stem [Read More]

Researchers discover how the body skillfully extinguishes inflammation
Researchers discover how the body skillfully extinguishes inflammation

Inflammation needs energy An important source for this energy is oxygen, which is indispensable for the cells of the [Read More]

MS patients who feel stigmatized more likely to suffer from depression
MS patients who feel stigmatized more likely to suffer from depression

People with Multiple Sclerosis -- MS -- who feel stigmatized are more likely to suffer from depression, according to [Read More]

Stigma increases risk of depression for people with Multiple Sclerosis
Stigma increases risk of depression for people with Multiple Sclerosis

(Penn State) People with Multiple Sclerosis -- MS -- who feel stigmatized are more likely to suffer from depression, [Read More]